osmo

Source

underline

  1. Market Scope. Report on the Global Dry Eye Market. St. Louis, Mo: Market Scope, July 2004.
  2. Rolando M, Barabino S, Mingari C, Moretti S, Giuffrida S, Calabria G. Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eyes. Cornea. 2005;24:951-954.
  3. Clinical Trial #AG9689-001. Data on file, Allergan, Inc.
  4. Data on file, Allergan, Inc.
  5. Noecker RJ. Comparison of initial treatment response to two enhanced-viscosity artificial tears. Eye and Contact Lens. 2006; 32(3):148-152.
  6. Sharma A. Surface-chemical pathways of the tear film breakup. Does corneal mucus have a role? Adv Exp Med Biol. 1998;438;361-370.
  7. Garrett G, et al. CMC binds to human corneal epithelial cells through glucose-binding sites and stimulates cell migration. Presented at: Annual Meeting of the American Academy of Optometry; December 2006; San Diego, Calif.
  8. Noecker RJ. Eye drops: Purite may be gentler preservative for lubrication solutions. Stabilized oxychloro complex shows no cytotoxic effects to the corneal surface. Ophthalmol Times. 2001;26(21):72-75.
  9. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18;205-215.
  10. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003; 136: 2318-326.
  11. Stern ME, Gao T, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Ex Eye Res. 2004; 78:409-416.
  12. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900-907.
  13. Nelson JD, Helms H. Fiscella R, Southwell Y, Hirsh JD. A new look at dry eye disease and its treatment. Adv Ther. 2000;17:84-93.
  14. Albietz JM. Dry eye: an update on clinical diagnosis, management and promising new treatments. Clin Exp Optom. 2001;84:4-18.
  15. Schaumberg DA, Buring JE, Sulivan, JE, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114-2119.
  16. Way WA, et al. PuriteŽ as a nondisruptive preservative for lubricating eye drop solutions in comparison to alternative preservatives. Presented at the Association for Research in Vision and Ophthalmology (ARVO), 2001 and published abstract reference: Investigative Ophthalmology and Visual Science 2001;42(4):S39.
  17. Corfield AP, Shukla AK. Mucins: Vital Components of the Mucosal Defensive Barrier. International Scientific Communications, Inc. February 2003;GPT:20-23.
© Copyright 2007, Allergan Inc., all rights reserved. ® and ™ marks owned by Allergan, Inc.